Literature DB >> 9114203

Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital.

J F John1, N O Fishman.   

Abstract

Controlling antimicrobial costs has preoccupied infectious diseases physicians (IDPs). IDPs have controlled antimicrobial costs by the use of eight strategies: education, formulary restriction, pharmacy justification, formulary substitution, computer surveillance, laboratory item cost listing, purchase plans, and multidisciplinary approaches. Most strategies had input from IDPs and resulted in cost savings (up to $500,000 annually), particularly during the initiation periods. Educational efforts were successful in reducing costs but needed continual intervention. Formulary restriction was the most straightforward cost-control mechanism. Restriction of "target antimicrobials" has given way to "switch" therapy between expensive and less costly agents or between parenteral and oral regimens. Switch therapy is facilitated through the use of innovative order forms and on-line computer interaction. Computer surveillance has a capacity for interactive controls. Purchase plans may give way to centralized pharmacy monitoring, a strategy that is attractive to managed care organizations. Multidisciplinary antimicrobial management programs (AMPs) offer the best potential for sustaining savings in antimicrobial costs. Ten recommendations lay a groundwork for IDPs to translate their expertise into leadership of AMPs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114203     DOI: 10.1093/clinids/24.3.471

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Antimicrobial utilization and bacterial resistance at three different hospitals.

Authors:  V Vlahović-Palcevski; M Morović; G Palcevski; L Betica-Radić
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital.

Authors:  Jian Shen; Qingmin Sun; Xianmei Zhou; Yu Wei; Yongjian Qi; Jiping Zhu; Tingting Yan
Journal:  Int J Clin Pharm       Date:  2011-11-09

3.  Clinical benefit of infectious diseases consultation: a monocentric prospective cohort study.

Authors:  A de La Blanchardière; J Boutemy; P Thibon; J Michon; R Verdon; V Cattoir
Journal:  Infection       Date:  2012-06-22       Impact factor: 3.553

Review 4.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  Antimicrobial stewardship in acute care centres: A survey of 68 hospitals in Quebec.

Authors:  Vincent Nault; Mathieu Beaudoin; Daniel Jg Thirion; Michel Gosselin; Benoit Cossette; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-05       Impact factor: 2.471

6.  Antibiotic stewardship in Germany: a cross-sectional questionnaire survey of 355 intensive care units.

Authors:  F Maechler; F Schwab; C Geffers; E Meyer; R Leistner; P Gastmeier
Journal:  Infection       Date:  2013-10-18       Impact factor: 3.553

7.  Effect of communication errors during calls to an antimicrobial stewardship program.

Authors:  Darren R Linkin; Neil O Fishman; J Richard Landis; Todd D Barton; Steven Gluckman; Jay Kostman; Joshua P Metlay
Journal:  Infect Control Hosp Epidemiol       Date:  2007-11-01       Impact factor: 3.254

8.  Antimicrobial stewardship - can we afford to do without it?

Authors:  Anna Aryee; Nicholas Price
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

9.  Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit.

Authors:  E Meyer; F Schwab; A Pollitt; W Bettolo; B Schroeren-Boersch; M Trautmann
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

Review 10.  Pro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?

Authors:  Philip George; Andrew M Morris
Journal:  Crit Care       Date:  2010-02-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.